Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Consumers Complain To FDA About Albuterol Inhalers, Oxycontin Abuse

Executive Summary

The ombudsman for FDA's Center for Drug Evaluation and Research fielded 660 complaints last year ranging from drug shortage problems to off-label drug promotion and study protocol violations
Advertisement

Related Content

CDER Ombudsman Referees Increasing Number Of Internal Scientific Disputes
CDER Ombudsman Referees Increasing Number Of Internal Scientific Disputes
Can A REMS Block A Generic? Thalomid Could Be Early Test
Can A REMS Block A Generic? Thalomid Could Be Early Test
As Deadline For CFC Inhalers Looms, Firms Offer Incentives For HFA Switch
As Deadline For CFC Inhalers Looms, Firms Offer Incentives For HFA Switch
Ketek Is Emerging As Lens For Wider Hill Scrutiny Of Clinical Trial Integrity
Advertisement
UsernamePublicRestriction

Register

PS049778

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel